Table 1.
Demographic and clinical characteristics of study participants used for cytokine and chemokine mRNA real-time PCR low-density arrays
| Uninflamed | Resolving arthritis | Early RA | Established RA | |
|---|---|---|---|---|
| Number | 10 | 9 | 17 | 12 |
| Symptom duration (weeks); median (IQR) | na | 5 (2–9) | 6 (4–9) | 38 (27–52) |
| Female; n (%) | 5 (50) | 3 (33) | 12 (71) | 6 (50) |
| Age years; median (IQR) | 43 (37–48) | 40 (30–69) | 53 (48–59) | 60 (48–67) |
| RF and/or anti-CCP positive; n (%) | na | 0 (0) | 8 (47) | 7 (58) |
| Global disease-related variables | ||||
| CRP; median (IQR) | na | 10 (8–22) | 12 (5–32) | 17 (7–52) |
| ESR; median (IQR) | na | 24 (8–48) | 25 (14–58) | 28 (12–55) |
| DAS28; median (IQR) | na | 4.1 (3.4–4.6) | 4.7 (4.2–6.0) | 5.4 (4.7–6.6) |
| Biopsied joint-related variables | ||||
| Joint biopsied | ||||
| Ankle; n (%) | 0 (0) | 3 (33.3) | 4 (24) | 2 (17) |
| Knee; n (%) | 10 (100) | 6 (66.6) | 10 (59) | 10 (83) |
| MCP joint; n (%) | 0 (0) | 0 (0) | 3 (18) | 0 (0) |
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, Disease Activity Score in 28 Joints; ESR, erythrocyte sedimentation rate; MCP, metacarpophalangeal; na, not available; RF, rheumatoid factor.